0001171843-24-001322.txt : 20240313 0001171843-24-001322.hdr.sgml : 20240313 20240313161013 ACCESSION NUMBER: 0001171843-24-001322 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240313 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240313 DATE AS OF CHANGE: 20240313 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Anika Therapeutics, Inc. CENTRAL INDEX KEY: 0000898437 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 043145961 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14027 FILM NUMBER: 24746008 BUSINESS ADDRESS: STREET 1: 32 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: (781) 457-9000 MAIL ADDRESS: STREET 1: 32 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 FORMER COMPANY: FORMER CONFORMED NAME: ANIKA THERAPEUTICS INC DATE OF NAME CHANGE: 19970114 FORMER COMPANY: FORMER CONFORMED NAME: ANIKA RESEARCH INC DATE OF NAME CHANGE: 19930309 8-K 1 f8k_031324.htm FORM 8-K Form 8-K
0000898437 False 0000898437 2024-03-13 2024-03-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  March 13, 2024

_______________________________

Anika Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware001-1402704-3145961
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

32 Wiggins Avenue

Bedford, Massachusetts 01730

(Address of Principal Executive Offices) (Zip Code)

(781) 457-9000

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareANIKNASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
Item 2.02. Results of Operations and Financial Condition.

The following information, including the exhibit attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

On March 13, 2024, Anika Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number Description
      
99.1 Press Release of Anika Therapeutics, Inc. dated March 13, 2024
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 Anika Therapeutics, Inc.
   
  
Date: March 13, 2024By: /s/ CHERYL R. BLANCHARD        
  CHERYL R. BLANCHARD
  President and Chief Executive Officer
  

 

 EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

Anika Reports Fourth Quarter and Year-End 2023 Financial Results

Revenue growth and adjusted EBITDA1 exceeded expectations in the fourth quarter and full year

OA Pain Management achieved record annual revenues of $102 million, up 11% in 2023

Announces cost reduction initiatives providing annualized savings of approximately $10 million

Anika positioned to generate adjusted EBITDA1 of $25 to $30 million in 2024, up over 75% at the midpoint, representing an adjusted EBITDA1 margin of at least 15%

BEDFORD, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its fourth quarter and full year ended December 31, 2023.

Fourth Quarter 2023 Financial Summary

  • Revenue in the fourth quarter of 2023 was $43.0 million, up 8% compared to $39.6 million in the fourth quarter of 2022.
    • OA Pain Management revenue of $25.1 million, up 12%, on growing global commercial adoption and some order timing
    • Joint Preservation and Restoration revenue of $15.3 million, up 7%
    • Non-Orthopedic revenue of $2.6 million, down 8%
  • Gross margin was 61%, including $1.6 million of non-cash acquisition-related intangible asset amortization; Adjusted gross margin1 was 65%.
  • Recorded a non-recurring, non-cash impairment charge in the fourth quarter of $62.2 million for the intangible assets associated with the Q1-2020 acquisitions of Arthrosurface and Parcus Medical.
  • Including the non-cash impairment charge, net loss was ($63.0) million, or ($4.30) per share, compared to net loss of ($4.9) million, or ($0.34) per share, in the prior year period.
  • Adjusted net income1 was $0.8 million, or $0.05 per diluted share, compared to adjusted net loss1 of ($3.0) million, or ($0.21) per share, in the fourth quarter of 2022.
  • Adjusted EBITDA1 was $5.8 million, compared to $1.4 million in the fourth quarter of 2022.
  • Cash from operations was $3.6 million; ending cash balance rose to $72.9 million.

Full Year 2023 Financial Summary

  • Revenue for fiscal 2023 increased 7% to $166.7 million, compared with $156.2 million in 2022.
    • OA Pain Management revenue of $101.9 million, up 11%
    • Joint Preservation and Restoration revenue of $54.9 million, up 9%
    • Non-Orthopedic revenue of $9.9 million, down 29%
  • Gross margin was 62%, including $6.2 million of non-cash acquisition-related intangible asset amortization and $0.7 million of product rationalization charges. Adjusted gross margin1, excluding these charges, was 66%.
  • Including the fourth quarter non-cash impairment charge, net loss was ($82.7) million, or ($5.64) per share, compared to net loss of ($14.9) million, or ($1.02) per share, in 2022. Net loss also included $18.1 million, or ($1.23) per share, for charges associated with product rationalization, acquisition related amortization, discontinuation of software development, Parcus arbitration settlement and shareholder activism.
  • Adjusted net loss1 for the year was ($4.3) million, or ($0.30) per share, compared to adjusted net loss of ($7.1) million, or ($0.49) per share in 2022.
  • Adjusted EBITDA1 for the year was $15.5 million, compared to $12.6 million in 2022.
  • Cash used in operations was $1.8 million.

1 See description of non-GAAP financial information contained in this release.

“We are pleased to report strong fourth quarter and full year results, including a record year in OA Pain Management. These results reflect the evolution of our differentiated HA franchise and the launch of exciting new products in Regenerative, Sports Medicine and Arthrosurface Joint Solutions,” said Cheryl R. Blanchard, Ph.D., Anika’s President and CEO. “Over the course of the year, we achieved key milestones, learned a lot about the business, and are taking decisive action to further reduce spending and focus our strategy on driving the products that provide the greatest growth opportunities. Our plan to optimize performance is designed to capitalize on the significant growth potential across the business while accelerating our pivot to profitability, with adjusted EBITDA expected to grow over 75% at the midpoint in 2024.”

Dr. Blanchard continued, “We begin 2024 with renewed energy and strong momentum across the new products in our portfolio. Our HA-based Integrity Implant System is receiving very positive feedback, and its full market release is on track for mid-2024. We also remain focused on bringing Hyalofast and Cingal to the U.S. market. As we focus the business on our core strengths and highest value opportunities, we are confident that we will enhance value for shareholders.”

Fiscal 2023 and Recent Business Highlights

  • Strengthening Leadership Position in OA Pain Management
    • Achieved record annual revenues of $102 million in OA Pain Management on global growth of its Monovisc® single injection viscosupplement and continued double-digit international growth of its Cingal® next generation non-opioid single injection pain product, on growing global commercial adoption and some order timing; increasing #1 U.S. market share position2.
    • Awaiting FDA feedback on proposed non-clinical next steps regarding Cingal U.S. regulatory approval following a Type C meeting with the FDA in early 2023 and its success in meeting its latest Phase III Pivotal primary endpoint in the fall of 2022.
    • Continuing to explore commercial partnerships for Cingal in the U.S. and select Asian markets.
  • Advancing a Highly Differentiated Portfolio of HA-Based Regenerative Solutions
    • Successfully completed over 100 cases with the Integrity™ Implant System, Anika’s HA-based regenerative rotator cuff patch system, following the limited market release in late November 2023; on-track for full market release in mid-2024
    • Fully enrolled Phase III clinical trial for Hyalofast®, Anika’s HA, off-the-shelf, single-stage cartilage repair product; modular PMA submission with break-through device designation commencing in 2024; final PMA module filing expected in 2025 with product launching by 2026.
  • Launched Key Products in Sports Medicine and Arthrosurface Joint Solutions
    • X-Twist™ Biocomposite Fixation System launched in Q1-2024, compliments the PEEK version launched in early 2023, together addressing the more than $600 million U.S. rotator cuff market2.
    • RevoMotion™ Reverse Shoulder Arthroplasty System full market release in September 2023, expanding Anika’s shoulder arthroplasty portfolio into the more than $1 billion U.S. reverse shoulder market2.

2 SmartTRAK Q3-2023 data

Cost Reductions
In 2023, Anika launched multiple meaningful new products and made considerable progress addressing the new MDR regulatory requirements in Europe. With the progress made in 2023, and in recognition of the slower than expected pace of growth in some of its more mature product lines, the Company has decided to further reduce its planned spending for 2024 and to reduce approximately 9% of its workforce, effective the end of the first quarter. The cost reductions, on an annualized basis, are expected to provide savings of approximately $10 million, excluding the impact of one-time costs. These actions position Anika to focus on its strengths and preserve the Company’s significant opportunities with its strong, growing and differentiated product lines and pipeline, and accelerate Anika’s pivot to profitability.

Fiscal 2024 Guidance
In 2024, Anika is prioritizing accelerated growth in profitability, with a focus on the products with the greatest growth opportunities and where the Company has the most differentiated right-to-win.

As such, Anika expects revenue for fiscal year 2024 of $168 to $173 million, representing growth of 1% to 4% compared to 2023. Revenue ranges by product family are:

  • OA Pain Management of $102 to $104 million, up 0% to 2%, on sustained above-market growth offset by some unfavorable order timing
  • Joint Preservation and Restoration of $58 to $60.5 million, up 6% to 10%
  • Non-Orthopedic of $8 to $8.5 million, down 14% to 19%

The Company expects adjusted EBITDA for 2024 to be $25 to $30 million, up over 75% at the midpoint, representing an adjusted EBITDA margin of at least 15%, up over 6 points compared to 2023. Anika’s expectations around improved profitability in 2024 reflect only partial-year cost savings as well as the early-stage ramp from Anika’s new products.

Strategic Business Update
Beginning in mid-2023, Anika engaged Piper Sandler and conducted a company-wide strategic review, evaluating a wide range of strategic alternatives for the company to increase shareholder value, including a potential sale. Anika remains open to all value enhancing opportunities and regularly reviews what makes the most sense for the business.

Conference Call and Webcast Information
Anika’s management will hold a conference call and webcast to discuss its financial results and business highlights today, Wednesday, March 13, 2024, at 5:00 pm ET. The conference call can be accessed by dialing 1-888-886-7786 (toll-free domestic) or 1-416-764-8658 (international) and providing the conference ID number 19479013. A live audio webcast will be available in the Investor Relations section of Anika’s website, www.anika.com. A slide presentation with highlights from the conference call will be available in the Investor Relations section of the Anika website. A replay of the webcast will be available on Anika’s website approximately two hours after the completion of the event.

About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.

ANIKA, ANIKA THERAPEUTICS, ARTHROSURFACE, CINGAL, HYALOFAST, INTEGRITY, MONOVISC, PARCUS MEDICAL, REVOMOTION, X-TWIST, and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.

Non-GAAP Financial Information
Non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with GAAP. Furthermore, the Company’s definition of non-GAAP measures may differ from similarly titled measures used by others. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, Anika strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. The Company presents these non-GAAP financial measures because it uses them as supplemental measures in internally assessing the Company’s operating performance, and, in the case of Adjusted EBITDA, it is set as a key performance metric to determine executive compensation. The Company also recognizes that these non-GAAP measures are commonly used in determining business performance more broadly and believes that they are helpful to investors, securities analysts, and other interested parties as a measure of comparative operating performance from period to period.

Adjusted Gross Margin
Adjusted gross margin is defined by the Company as adjusted gross profit divided by total revenue. The Company defines adjusted gross profit as GAAP gross profit excluding amortization of certain acquired assets and non-cash product rationalization charges.

Adjusted EBITDA
Adjusted EBITDA is defined by the Company as GAAP net income (loss) excluding depreciation and amortization, interest and other income (expense), income taxes, stock-based compensation expense, acquisition related expenses, non-cash charges related to goodwill impairment, non-cash product rationalization charges and charges related to discontinuation of a software project.

Adjusted Net Income (Loss) and Adjusted EPS
Adjusted net income (loss) is defined by the Company as GAAP net income excluding acquisition related expenses, inclusive of the impact of purchase accounting, on a tax effected basis, non-cash charges related to goodwill impairment, non-cash product rationalization charges and charges related to discontinuation of a software project. Adjusted diluted EPS is defined by the Company as GAAP diluted EPS excluding acquisition related expenses and the impact of purchase accounting, each on a tax-adjusted per share basis, non-cash product rationalization charges and charges related to discontinuation of a software development project.

A reconciliation of adjusted gross profit to gross profit (and the associated adjusted gross margin calculation), adjusted EBITDA to net income (loss), adjusted net income (loss) to net income (loss) and adjusted diluted EPS to diluted EPS, the most directly comparable financial measures calculated and presented in accordance with GAAP, is shown in the tables at the end of this release.

Forward-Looking Statements
This press release may contain forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning the Company's expectations, anticipations, intentions, beliefs or strategies regarding the future which are not statements of historical fact, including statements in the sub-headings, Dr. Blanchard’s quote, and the section titled Cost Reductions about potential cost savings and future profitability, the statements in Dr. Blanchard’s quote and the section titled Fiscal 2023 and Recent Business Highlights about the timing of future product launches, and the statements made in the section titled Fiscal 2024 Guidance. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks, uncertainties, and other factors. The Company's actual results could differ materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors including, but not limited to, (i) the Company's ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all; (ii) the Company's ability to obtain pre-clinical or clinical data to support domestic and international pre-market approval applications, 510(k) applications, or new drug applications, or to timely file and receive FDA or other regulatory approvals or clearances of its products; (iii) that such approvals will not be obtained in a timely manner or without the need for additional clinical trials, other testing or regulatory submissions, as applicable; (iv) the Company's research and product development efforts and their relative success, including whether we have any meaningful sales of any new products resulting from such efforts; (v) the cost effectiveness and efficiency of the Company's clinical studies, manufacturing operations, and production planning; (vi) the strength of the economies in which the Company operates or will be operating, as well as the political stability of any of those geographic areas; (vii) future determinations by the Company to allocate resources to products and in directions not presently contemplated; (viii) the Company's ability to successfully commercialize its products, in the U.S. and abroad; (ix) the Company's ability to provide an adequate and timely supply of its products to its customers; and (x) the Company's ability to achieve its growth targets. Additional factors and risks are described in the Company's periodic reports filed with the Securities and Exchange Commission, and they are available on the SEC's website at www.sec.gov. Forward-looking statements are made based on information available to the Company on the date of this press release, and the Company assumes no obligation to update the information contained in this press release.

For Investor Inquiries:
Anika Therapeutics, Inc.
Mark Namaroff, 781-457-9287
Vice President, Investor Relations, ESG and Corporate Communications
investorrelations@anika.com

 
Anika Therapeutics, Inc. and Subsidiaries
Consolidated Statements of Operations
(in thousands, except per share data)
(unaudited)
            
 For the Three Months Ended December 31,
 For the Twelve Months Ended December 31,
 2023 2022 2023 2022
Revenue$42,971  $39,622  $166,662  $156,236 
Cost of Revenue16,642  15,491  63,574  62,660 
Gross Profit26,329  24,131  103,088  93,576 
            
Operating expenses:           
Research and development7,585  7,749  32,690  28,182 
Selling, general and administrative20,335  23,049  95,847  84,794 
Impairment of intangible assets62,190  -  62,190  - 
Total operating expenses90,110  30,798  190,727  112,976 
Loss from operations(63,781) (6,667) (87,639) (19,400)
Interest and other income (expense), net577  276  2,312  654 
Loss before income taxes(63,204) (6,391) (85,327) (18,746)
Benefit from income taxes(204) (1,483) (2,660) (3,887)
Net loss$(63,000) $(4,908) $(82,667) $(14,859)
            
Net loss per share:           
Basic$(4.30) $(0.34) $(5.64) $(1.02)
Diluted$(4.30) $(0.34) $(5.64) $(1.02)
            
Weighted average common shares outstanding:           
Basic14,647  14,640  14,656  14,561 
Diluted14,647  14,640  14,656  14,561 
            

 

Anika Therapeutics, Inc. and Subsidiaries
Consolidated Balance Sheets
(in thousands, except per share data)
(unaudited)
      
 December 31, December 31,
ASSETS2023 2022
Current assets:     
Cash and cash equivalents$72,867  $86,327 
Accounts receivable, net35,961  34,627 
Inventories, net46,386  39,765 
Prepaid expenses and other current assets8,095  8,828 
Total current assets163,309  169,547 
Property and equipment, net46,198  48,279 
Right-of-use assets28,767  30,696 
Other long-term assets18,672  17,219 
Deferred tax assets1,489  1,449 
Intangible assets, net4,626  74,599 
Goodwill7,571  7,339 
Total assets$270,632  $349,128 
      
LIABILITIES AND STOCKHOLDERS’ EQUITY     
Current liabilities:     
Accounts payable$9,860  $9,074 
Accrued expenses and other current liabilities21,199  18,840 
Total current liabilities31,059  27,914 
Other long-term liabilities404  398 
Deferred tax liability-  6,436 
Lease liabilities26,904  28,817 
      
Stockholders’ equity:     
Common stock, $0.01 par value147  146 
Additional paid-in-capital90,009  81,141 
Accumulated other comprehensive loss(5,943) (6,443)
Retained earnings128,052  210,719 
Total stockholders’ equity212,265  285,563 
Total liabilities and stockholders’ equity$270,632  $349,128 
      

 

Anika Therapeutics, Inc. and Subsidiaries 
Reconciliation of GAAP Gross Profit to Adjusted Gross Profit  
(in thousands) 
(unaudited) 
            
            
 For the Three Months Ended December 31, For the Twelve Months Ended December 31,
 2023 2022 2023 2022
Gross Profit$26,329  $24,131  $103,088  $93,576 
Product rationalization related charges-  563  748  3,199 
Acquisition related intangible asset amortization1,560  1,560  6,244  6,240 
Adjusted Gross Profit$27,889  $26,254  $110,080  $103,015 
            
Unadjusted Gross Margin61% 61% 62% 60%
Adjusted Gross Margin65% 66% 66% 66%
            


Anika Therapeutics, Inc. and Subsidiaries     
Reconciliation of GAAP Net Income to Adjusted EBITDA     
(in thousands)     
(unaudited) 
            
 For the Three Months Ended December 31, For the Twelve Months Ended December 31,
 2023 2022 2023 2022
Net loss$(63,000) $(4,908) $(82,667) $                (14,859)
Interest and other (income) expense, net(577) (276) (2,312) (654)
Benefit from income taxes(204) (1,483) (2,660) (3,887)
Depreciation and amortization1,787  1,880  7,069  7,340 
Stock-based compensation3,815  3,813  15,243  14,315 
Product rationalization-  563  748  3,199 
Arbitration settlement-  -  3,250  - 
Acquisition related intangible asset amortization1,787  1,786  7,148  7,147 
Impairment of intangible assets62,190  -  62,190  - 
Discontinuation of software development project-  -  4,473  - 
Costs of shareholder activism-  -  3,033  - 
Adjusted EBITDA$        5,798  $ 1,375  $    15,515  $   12,601 
            


Anika Therapeutics, Inc. and Subsidiaries     
Reconciliation of GAAP Net Income to Adjusted Net Income     
(in thousands)     
(unaudited) 
            
 For the Three Months Ended December 31, For the Twelve Months Ended December 31,
 2023 2022 2023 2022
Net loss$(63,000) $(4,908) $(82,667) $                (14,859)
Product rationalization, tax effected-  456  725  2,410 
Arbitration settlement, tax effected-  -  3,148  - 
Acquisition related intangible asset amortization, tax effected1,781  1,446  6,926  5,386 
Impairment of intangible assets, tax effected61,991  -  60,250  - 
Discontinuation of software development project, tax effected-  -  4,333  - 
Costs of shareholder activism, tax effected-  -  2,938  - 
Adjusted net income (loss)$     772  $ (3,006) $  (4,347) $(7,063)
            


Anika Therapeutics, Inc. and Subsidiaries     
Reconciliation of GAAP Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share     
(in thousands, except per share data)     
(unaudited) 
            
 For the Three Months Ended December 31, For the Twelve Months Ended December 31,
 2023 2022 2023 2022
Diluted net loss per share$(4.30) $(0.34) $(5.64) $(1.02)
Product rationalization, tax effected-  0.03  0.05  0.17 
Arbitration settlement, tax effected-  -  0.21  - 
Acquisition related intangible asset amortization, tax effected0.12  0.10  0.47  0.36 
Impairment of intangible assets, tax effected4.23  -  4.11  - 
Discontinuation of software development project, tax effected-  -  0.30  - 
Costs of shareholder activism, tax effected-  -  0.20  - 
Adjusted diluted net income (loss) per share$0.05  $(0.21) $(0.30) $(0.49)
            
            
Stock-based compensation, tax effected3,803  3,088  14,767  10,783 
Stock-based compensation (EPS impact)$0.26  $0.21  $1.01  $0.74 
            


Anika Therapeutics, Inc. and Subsidiaries
Revenue by Product Family
(in thousands, except percentages)
(unaudited)
                    
 For the Three Months Ended December 31,
 For the Twelve Months Ended December 31,
 2023 2022 $ change % change 2023 2022 $ change % change
OA Pain Management$25,072 $22,451 $2,621  12% $101,927 $91,984 $9,943  11%
Joint Preservation and Restoration15,296 14,347 949  7% 54,879 50,402 4,477  9%
Non-Orthopedic2,603 2,824 (221) -8% 9,856 13,850 (3,994) -29%
Revenue$42,971 $39,622 $3,349  8% $166,662 $156,236 $10,426  7%
                    

 EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Mar. 13, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 13, 2024
Entity File Number 001-14027
Entity Registrant Name Anika Therapeutics, Inc.
Entity Central Index Key 0000898437
Entity Tax Identification Number 04-3145961
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 32 Wiggins Avenue
Entity Address, City or Town Bedford
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01730
City Area Code 781
Local Phone Number 457-9000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol ANIK
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_031324.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "f8k_031324.htm": { "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "dts": { "inline": { "local": [ "f8k_031324.htm" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://globenewswire.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Form8K", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_031324.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Form8K", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_031324.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001171843-24-001322-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-24-001322-xbrl.zip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

M]K>(RS@#']83T3-WOE_[+MK+LRI.0$@>4N?."X8_L"M=;[S; M&I5)Y.Z%V$1R*#=K> ]-#^4?OW1E[]PV-_+?OL3T<=',9W)'!=P\WVR559ET M?NKV__65]$ODX]?V7>>G=O\V7:<.^?=-M-W*8?1M"&,Q,[^!9/JYSH2ST<8] M%_FF'I<^8DA:+?,+;:L)MJ[2WR0%#K1F;V::D M?[]KP DD) JTY;8)KS>9!P]4Z69%$LOF$P]1$4D8R;2I??XX']Y MN+F[\]#UU:>/H8Z>:$80,(1>>D_&Y N,R[*35P ML>%,_.V#!_/Y'%>S#GJ W*P5=](S;*?71-.M,LRR$W@FM"$BZN!CLR6TP9]Q M/=F!LE[H90UE#AK3/9RFT225SQ@F '\Q<\!"^RDA^1:<$+VN1)N)#E@KJI#2$6YA:9FBE0+@2BVG"!*LR3NLG0#ZZ ME5%A6X1A10GQ/K@E46@:?Q=7U3A75 .O:F$%@8;80(Z0(L*C@@_C[$KII30! MMU2[Q7.[Y"=-4+6[%M8'2T^S+.=V+U2Q)T63I0=^\-TG^@.=3< F#F&53VRN M:N'W%Z/)ZR2(B@Y4#C8_B,B<*L/ JZT=7E?.C*7_:*5!-H_V$'Z#CCE9#^T8 M*)2_8ZLKJ_^6/8*-AO;8==X[-7J[3=+NMCD1\.Y(:-[WCXT0^I;*('%P")VZ M!^H;;"6C2NH$Q;[YCN?;D!]<^+-@LM'QKM(A1>R685@1CC>BB".W45]^?0QN M![X=G)OTR*UV,FDO!U-NM(N,+J%]![ZBADIF4!&=SQD;A:T$%E+X BX>Q:+S MC-!FWM=$ZX2Y=4)P^AGBR37$OXXRQ^Y$ZSQ,.7_O! M_EN-33O"D(?)^]P8XEH-AO\!4$L#!!0 ( $:!;5BO[VJ!40@ (=D 4 M 9VYW+3(P,3DP,3 Q7V1E9BYX;6S575UOX[@5?2_0_V"XSX[B9*?;!),N M/)ZD,'9FXL;9;MN7@)9HF0A%&B05V_^^I#X*5Y&W"2'E(;/F0//<Q?GYV/OW M]V\+?XTC-"+,U.?C85[*U&(K-[ZZNO*23W-H!;E;"IJW<>GE= XUZT\#=2A0 M!'_RT@^+4%)3=8&T)-0;]Y%*E&MD- 1YMTHAXW,H='X8G0Y/MO)8*B% M'NB?5&S!*7[ JX'Y^]O#[-!J2/D2,[R56R+PF<\CSR"\*=?&:KI)V;7 JYMA MR+:ZA?'5^?@\J?\O)8S:;[2_DD0;JL/T2FTCX>?-V\#%1H!(<\%-B)^2QM>Z M"N''2SP*2(29Z8/#0=90,;Y#+80I3T.]#.-9*WA_WH?&1@&/$#F1=+6T \9) M2Z,(1TMC]TETRT7?GRNB]#2&28'WY\6XFIQ*+2_CM$_B%8JI^L.=,B]>YJP/ M$T;,8/=-ORWQQCN%68"#G+FI\*2Q21%E2IRG/^/!:/"5^[$FI/3+%)EQR=E0 M[I $5+3)-FGS*P#>M]+.M'M'SM3C6,,]PQVU?')R+GG767EN=DVD>O M?UIR_F[3HA.4/Z&^E30D_U_=RK]88TIUGWO7W6K/\M4T3M[PC%/V+@/IF& M':,ZK;>5+*BSHTPW)96G?DS]0!'0QVW('NAM(0QJ[BB?38E--7V!Z(P%>/)?@3M@>HVQJ#LCG+:E-EFG!1;T% MCC)?B-WE:19<]M*"R_K'8(ZRX!*[J7YY+Q[Y%GCZ"(#[(_\19U!\IREPQBV) MYE[,!7\AZ6:')@>.2O3'!AMQT NG:7+>3]+I0INS($7V1_LB85!SIVER1FS. MI4+TOV33-#NUX?NC?Y4VZ(*CK#GK$>8V"K3LI 3IM-95IJ"\CE)C<\V9"(S@ M;EU$=%O<8Z*@MH[RW&^Z#CI?,[K7X#;= % M1VGF$;V9E#$6IWI1*=4G1^SD05\[\-6(AAE=TV)"=%ALD#&KN*--\'=C"5F-UV*>Q.FPQ5CO*-'-2Z4)E M?=[=+RD)$;PCJJ9 +]2'>(-&.,I/T_TJ,[;B(DI8W>D7=@NLT$Z+#S,&97>4 MGT[B@"@R"_C3$HN].'I-FR M\L.5RP05UZIO+]$#$VJ(@UXX?7@Z8PH+Y"OR@K\BA3*^=5[82_3 BQKBH!=. M%QXG)^I4QQ/R^K4#)6 /E*_R!05WNMYX$2%*O\12!R!KQY\2L >"5_F"@CM= M47P;81'J8? ?@F_5.MO(6">\M4 /#(!Y@T8X73E\NWO=6)UNK:MUH8+N@P5V MTJ#^CG?*3GS?+#5)YP0L0 )P ,9WVH,&VJ +CM+D>[7&HC@K2ZB98.H6@C25 MZK0CK6H=MY?@/5 ZV.V MH-1.,]\OB#V+>*/\_5QP'V/S8$@>SLD6R5>K"GI@3_LX0./<;L5-OD(R^7+# MQ1H)+.]CE?QG!V-1('W3'\;=0R=SCXLG\P7S%I%F\\XIWZ MHAMZKI]<-1;OM%>G10%:5DB]/WM' >KFG_5GV7'SR_S+"WWD?U!+ P04 M" !&@6U89U'1\)8* "8A0 % &=N=RTR,#$Y,#$P,5]L86(N>&ULS9U= M;^.X%8;O"_0_$.Y-"XSCB0,42##91<:3%,9FDVSLV6V[*!:TQ#A"9-*@Y,3^ M]R4E499('DE)49)SD7'$]U OQ2CTY//(T1HQ.*$ MKB]'WQ?CJ\5L/A^A+,C''_[\IR]I0E\NY(\5S@@2]=#L8I\E MEZ/G/-]>3"9O;V\G;VN690F'?J&DRRYR I[MRS">7$X>G>#0(7\;:QD M8[EI?#H=GYV>[+-X)(X>$O_*(\A92A[)$RJ:>9$?MN(09\EFFTI3Q;9G3I[L M9E+.)S)^0LD:YR26.SJ7.SK]N]S17ZK-MWA%TA&2RN^/<[!=YZVZJJ"):[,/ MA"[*_R#'/_X<&-..=-V')TL M:M6;RM&<<;/MF:BWJ#,CT;7* T9:,DXSM>$3>U2M-M]!1JAQM4J&02PU"Q]\7HQ\*#?I=J?[S M97*LQ4%'?V/1;D-HOA0U6EK0+G;5S393JI>;94%TLL60WL=*@J3&<0=?B1W' MUHR9QW MNL6DT?<-35@(F,9@$AI:3P/[(UDG MB/AE)\[8"4\/O5 82M=< %9U-#194'38O8& U'*_C"PYIEDB![!>2$RI\],- MP*QQZJ'I@N($, >?DM1ZOZ0LGDF:SMAFBVG_@&(3NZ8%-JSS8BJ#(@:T!S)3 M1* J)!QLKE_EZEPLDP8VMJ'W"8]ANXN?6APL0KK#@10584C&>2*I<1NBAR%# MZ9H>P*K.C28+BAB[-Y"54HX*O7](KFD\")%:YP<0S:8=CTH4(!QM9WUH"+5/ M,&Z2+,)IZ>5&;,LZFF?1N@8$M*M#8@B# @5R!\)2!BAFBA"OP/R+8#X,EX;2 M#RR&53LJM2Q 4'1O?9A(O1=(9CO.6Z[A&0>6.KLIVV.VOC\+Z(( I<><<=>V ME+= \30#7=,\R0\W24KN=IL5X9;&F1)7;$#F%!-Z>1 L *9T!DH9DCI4"KWT MO+I+0/,[O+&-$':96P+L)ML4M#4!D6 U!M!PU"(I]D+$3(Q,'*=S&I/]3^0 MMLO0N64"L-F&0A,%1(7=&8!%)4:%&@FY%S >>++!_+!(HIZIPA2Z10,RVF9# M5P4$!V -H*-2H\5\YG,F6>+]/!:@)D])^3QX#R6@WBTL/;;;S #B@-#I=@@0 M)()0.\HG2',:,;YEC<<=9FPG!L##C,7P"J4GRBU4@YK01JLS)"# AO@$,&N% M?BJ?24&,HZH")&OP0MQ5'(L#E57_W2:4G(+MMVK=TM5AM\V411@02; [@)]* M^4E]0#(&W=-0H)F^HZE3_]!,AT(S#1J:Z4>@6;ZQ0* Y>T=3S_Q#.W6 ?/_6"6,5Y'6O*17GO'XF2^1EE MVB;M0TRI"0^2MK'>P:54^T3B@64Y3O^=;#M/Q.UB+WA8#5LA:2G#0\5FKP^8 M,@:)(!\GUA6N\H:&]54RK=S=*\ 66\=7@!N%04!@/2E%KKM9,LH) M!D:$=K&S3K:8JONX419&%YN&C!XN_JZ%QL1(\#IO1>+V2HT'FZ&B\S3&3VX;M1YFQFU^W4$[DJ"*)W=3?&-*W*'??F M;SS)Q9YG;+/9T>HNC^VY04#GJI<[;:H>MXJ"Z/TN9SH)E1:UQ8ZQ6+ TB9(\ MH>N?Q.)$0$M$1Q4N ,K$0 MOW]ZLL[V76)74/0;5G# RB @Z;6GPR("QE$C I4AJ(CQB\T\RW:$OPL>2X@G MA$#S $B&/D2<().]4)6!/ME:D&@GYL?#Z72U3/+4=G)I2IS-28"Y>D;2RH-@ M S"ELU"4(?:$3J=_7?T-J2C'W7_'EAS+I*J+PV;%4B#[E%7E"H(.BXH#BR0( M%&!?.@UW#%525&I]9*=JF;4T1RMW!8#5ENKZ5F$0G6YS9/SQM_K:TY!_O8^> MA2D"O)!@E[D>^FTF]>&_J0D"@0YCQDE))45*Z^.%A..4M>Y?!*R]+0+6/8N M=8B+@/701<#:VR) [;9,$2+&I?M5FJPQD)RP4^T:B@[+.A\6:5"HP/[ ,:,. M0<<8UQDMBQ1G<_K$^*;8_XWX8&DEH'.6T[++9IW4TB8*@I$N9T9:RS+I7$., MI-HU%[LXR4EG1A\'0,),&3F68RF58 M!QY37;J^E%X^@/$;2=.?*'NC"X(S1DE<7DNQW2GJUKM]8J;'=ONA&4 ;%N^3<-C(!.K?D #;;Q&BB@$BQ.P,( MJ<6H5/MY0;O,'E$OLN2 9TT!TRUW_+IVIVGMK6VK-B!F.@U"[W!7.3^.:^,R MRM,KECF1WQ>1O))O.,>5-["]D-SU2Y5=IO6W*6W:@!#J- B^/UG'R%0Q6#'E M+64,GXFEUIIU/"6NJ=PGCC$LFKEC:DE >-A\=620X4AIO;"PV. T_;K+$DHR M>"+25&Y9L%ILL]"2!,2"S1? 0B%%2NN%A>L-X6LQO?V#L[?\NUJRO*,@( ),5U"*O$*("J67_O^* MZ0O?;?/H\,!91(A\RBJK1ZN^ZV\#H]TR\ZXFM6D:%!H09^_Q"Q!XK (UZOC4 MF+%\7LR3#XW+;&XL>ED\8W$ [W=Y)F=080R^"MX9Y/CVPH &:#<9.B("0F^ M3>B&0Q&)BM!/J Q&C6A/YV?9,0L@B;\>'LD3X?*]@R79YU_%CEXZSC &Q+H^ M>QO<'/UDKC&ULS9S1 M[ A;&$UDB9'L &]?R086@R0?;GR2BX287_;YOV/+/K;D]Q_6*6^]4J69%#?M MWL5ENT5%)&,FDIMVKCM$1XRU6SHC(B9<"GK3%K+]X?=[NKU>IB-;B0*NGV+R][W7\^/TRB!4U)APF[OHBV=ZWL M6ESM>E=75]WBVYWT1+F>*;[;QJ"["V>_9O,M"^@/(M'L6A?A/LG__>A[OMYIP.:."KO2* M*7H1R;1K%=VA--DRX19M%XK.;]J)6)DM]*XN>Y?%^G^J:++-TB1-LW3)C9NU512ZJ8*L-ZMRZB MHDJ^3O?0K:*[),JLJ!,M&-^G>JYDZJ.S)2$]@1Z",IMHAN:MV7YL8QAQDKAQ M'DF /'L80)UNL(A^I#I2;&FYU("M*(%\^ZA\'=X:QKP[=IYIPFR\-I2)H43M MPG"_X&D"!#_ ["F";I$R<"M$3O@S74I5 [ZJ!/+^&9.WRQL2YC]SHC*J^ 9" M^D0,A/T+)FR/0R3>4T6$9I8/!/BI&DC\5]0+#X]').23!>5\*-,E$:"]W*4' M8G^'B=WO\PV OW^UYW=S:H&S/V@"Q/_;6\%_XA8I T]4,1F;4[H"L#\1 ZE? M85+W.$3E?2]B*.V]%%S_X,,^LH>$>L1T1'@9T<@LTV'<#CD4.4K-66L3%?N_ ME"@P] ,Q%#E*&5ICL6'@PURI2C#!7L6OAB)'*4#K3#;,_%YD+-N,&*=?\G3V M_<9IE?6I"LH8I>CTF4)AN[O3(+(O)/7LRVXEE#%*K1DRA\)Y:/PHPL6""]D*I<,K!SXCP$A"P^4:P]\_#WH=C1ZE#:VV^$>R#\[ /X-A1 M:M%:FYC8A^;CHYK*E><)M%<,18Y2B]98Q 1>G&D>U9.2KZP<'%5'_:0%%#UB MB1HVB[K#ER=YR-Z^4T)Y(Y:K;G.8G)^DS@C_CRWKKB3=>BASQ,(U9+3I&XQE MWNU-"]]0HB,)E"]*K>JTTS12FV%%B7_WK2J@0%$*4)>9AGD^2/OL8R%%\'[L MJ0K*%:62])EJNN.UHXFU]] _^!H\@@VE6SVVT3#&KXIE)H*A3--<;._1>)Z* M>:10O"CE7]!>PZ@GDK.(94PDG\T5HF*$NSF[=%#(*,6>WUC#A)\4M9FFYK*[ M&,=EIQNHQ_GO5%<\F.M]H!3^Z2%.(90P2H$7L-8P MY$H<;KQ'$BA8E,K.:0>I3[A?1PLB$NH?O>!60@&C5'HAY,S^UZ4 MBL]G"HEM.3;<'%&/,\X2XI])%FP GF>#23Q@M>GY>\64G[&82Y46<8S,!S=V MCQ0*'&>*9,A>TZCSF&4T+D,:,4%$9$JJ_;PV3W5>WPJ: )PYE$#3*+?WOU+. M/PFY$A-*M!0T+B_U0W?XO4V@64!\AEAC%R4%?TN>&TJJ& BJ/,> 1PI%COCL MT&,/9^QE.:AY?^ZQ!Z%OI'RX!10\XD/$L%FD\6D9M3&S5_J19&0;88B_KP64 M/^(#Q;!9M/'S:FA./(D,/S,_$D)I(PZ%=5I#@3Q)">=WN6:"ZF#?B(6IRQC.G*E\QEDTXI($K\LK,BA? MQ"K480L%[QT1+RI?9M'F2E9*'!N%\@TM9.) M9/0R61C3^C'/BM=[FOB"-PV"[:"IP9S$"3".=!6DOT_THO'=YIG.J;+#%*9T MG=V9#;V$+XH S:'Y07VC$!B#(TWONR>^'LP"^Z+:\AO[R[Z,U2SY'U!+ 0(4 M Q0 ( $:!;5AU(Q.X,"\ %*A @ + " 0 !E>&A? M.3DQ+FAT;5!+ 0(4 Q0 ( $:!;5ATM]XKJPT "8[ . M " 5DO !F.&M?,#,Q,S(T+FAT;5!+ 0(4 Q0 ( $:!;5B%)5>KL ( M -4+ 0 " 3 ] !G;G'-D4$L! A0# M% @ 1H%M6*_O:H%1" AV0 !0 ( !#D &=N=RTR M,#$Y,#$P,5]D968N>&UL4$L! A0#% @ 1H%M6&=1T?"6"@ F(4 !0 M ( !D4@ &=N=RTR,#$Y,#$P,5]L86(N>&UL4$L! A0#% M @ 1H%M6&S!0-7W!@ ]E8 !0 ( !65, &=N=RTR,#$Y B,#$P,5]P&UL4$L%!@ & 8 >0$ (): $! end XML 17 f8k_031324_htm.xml IDEA: XBRL DOCUMENT 0000898437 2024-03-13 2024-03-13 iso4217:USD shares iso4217:USD shares 0000898437 false 8-K 2024-03-13 Anika Therapeutics, Inc. DE 001-14027 04-3145961 32 Wiggins Avenue Bedford MA 01730 781 457-9000 false false false false Common Stock, par value $0.01 per share ANIK NASDAQ false